Scarica l'app Stockscreener
9.53
0.10%
-0.010
Dopo l'orario di chiusura:
9.55
0.02
+0.21%
Precedente Chiudi:
$9.54
Aprire:
$9.46
Volume 24 ore:
118.97K
Relative Volume:
1.32
Capitalizzazione di mercato:
$89.21M
Reddito:
$24.99M
Utile/perdita netta:
$-108.83M
Rapporto P/E:
-0.6341
EPS:
-15.0286
Flusso di cassa netto:
$-91.62M
1 W Prestazione:
+1.06%
1M Prestazione:
+17.51%
6M Prestazione:
+26.56%
1 anno Prestazione:
-25.84%
Intervallo 1D:
$9.31
$9.68
Intervallo di 1 settimana:
$9.261
$9.97
Portata 52W:
$6.01
$17.44
Adicet Bio Inc Stock (ACET) Company Profile
Nome
Adicet Bio Inc
Settore
Industria
Telefono
617-482-2333
Indirizzo
131 DARTMOUTH STREET, BOSTON
Compare ACET vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACET
Adicet Bio Inc
|
9.53 | 89.31M | 24.99M | -108.83M | -91.62M | -15.03 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Adicet Bio Inc Stock (ACET) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-09-30 | Ripresa | Guggenheim | Buy |
| 2024-09-11 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-06-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-06-27 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-06-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-09-21 | Iniziato | JP Morgan | Overweight |
| 2022-03-31 | Iniziato | SMBC Nikko | Outperform |
| 2022-03-08 | Iniziato | Truist | Buy |
| 2022-03-04 | Iniziato | Jefferies | Buy |
| 2021-05-18 | Iniziato | BTIG Research | Buy |
| 2021-04-23 | Iniziato | H.C. Wainwright | Buy |
| 2021-04-14 | Iniziato | Canaccord Genuity | Buy |
| 2021-04-08 | Iniziato | Guggenheim | Buy |
| 2020-11-04 | Iniziato | B. Riley Securities | Buy |
| 2020-10-27 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-10-16 | Iniziato | Wedbush | Outperform |
Mostra tutto
Adicet Bio Inc Borsa (ACET) Ultime notizie
Adicet Bio Highlights Prula-cel Autoimmune CAR-T Pipeline Progress - TipRanks
Adicet Bio posts September 2026 investor presentation outlining prula-cel and ADI-212 clinical timelines - TradingView
Adicet Bio Stock Price Forecast. Should You Buy ACET? - StockInvest.us
Wall Street Analysts See a 258.21% Upside in Adicet Bio (ACET): Can the Stock Really Move This High? - Yahoo Finance
Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Adicet Bio (NASDAQ:ACET) Upgraded to Strong-Buy at Jefferies Financial Group - MarketBeat
A biotech CEO will speak in New York Sept. 15. Audio will be online. - Stock Titan
Adicet Bio (NASDAQ: ACET) Advances ADI-212 Clinical Trial for mCRPC and Prepares Prula-Cel Data Release - Kalkine Media
Adicet Bio (NASDAQ: ACET) Advances ADI-212 Clinical Trial for mCRPC, Prula-cel Data Expected in September 2026 - Kalkine Media
Adicet Bio, Inc. (NASDAQ:ACET) Sees Large Drop in Short Interest - MarketBeat
Adicet Bio advances CAR-T programs and clinical pipeline - grafa.com
Adicet Bio completes prula-cel Phase 1 SLE analysis - TipRanks
Adicet Bio says prula-cel last patient visit complete; topline data due Sept 2026, ADI-212 IND cleared - TradingView
The final patient visit is complete in a lupus cell-therapy study. Adicet Bio expects results from 22 patients in September. - Stock Titan
Adicet Bio grants a new hire options on 1,500 shares over four years - Stock Titan
Adicet Bio (NASDAQ:ACET) Stock Rating Lowered by Wall Street Zen - MarketBeat
Press Release Service: Adicet Bio Announces FDA Clearance of IND Application for ADI-212 - CRISPR Medicine News
Adicet Bio Gets FDA Clearance for IND for ADI-212 in prostate cancer - marketscreener.com
Adicet Bio receives FDA clearance for prostate cancer trial By Investing.com - Investing.com Canada
Adicet Bio receives FDA clearance for prostate cancer trial - Investing.com
Here's Why You Should Add ACET Stock to Your Portfolio Now - Yahoo Finance
Adicet (ACET) Trading: Adds 0.32% to Close at $9.41 in the Current Update; Key Range - vinanet.vn
ETFs Investing in Adicet Bio Inc Stocks - TradingView
Are Medical Stocks Lagging Adicet Bio (ACET) This Year? - Eastern Progress
ACET Q2 2026 Earnings: Narrower-Than-Expected Loss of $1.99 Per Share Buoys SharesSegment Revenue Breakdown - vinanet.vn
RA Capital discloses 9.99% Adicet Bio (ACET) stake with warrant blocker - Stock Titan
Adicet Bio (ACET) - Zacks Investment Research
Adicet Bio: A Cheap Gamma Delta T-Cell Play (NASDAQ:ACET) - Seeking Alpha
Wall Street Analysts Think Adicet Bio (ACET) Could Surge 301.57%: Read This Before Placing a Bet - Zacks Investment Research
Adicet Bio (ACET) Edges Higher to $8.26 as Biotech Stock Consolidates Between Key LevelsETF Flow - Vinanet
HC Wainwright Has Strong Estimate for Adicet Bio Q3 Earnings - MarketBeat
Adicet Bio at Canaccord Genuity: lupus data drives next step By Investing.com - Investing.com Canada
Adicet Bio Eyes Key Lupus Data This Quarter for Off-the-Shelf Cell Therapy - MarketBeat
All You Need to Know About Adicet Bio (ACET) Rating Upgrade to Buy - newsbreak.com
H.C. Wainwright Maintains Adicet Bio(ACET.US) With Buy Rating, Maintains Target Price $27 - Moomoo
JonesTrading Maintains Adicet Bio(ACET.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Price to sales forward of Adicet Bio, Inc. – NASDAQ:ACET - TradingView
Adicet Bio Inc (ACET) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Press Release Service: Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates - CRISPR Medicine News
Guggenheim cuts Adicet Bio stock price target to $90 on cash position - Investing.com UK
CCORF Maintains Adicet Bio(ACET.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Adicet Bio, Inc. Stock 12‑Month Price Target Cut to $34.4, Implies 276% Upside - TradingView
ADICET BIO Q2 NET INCOME USD -21.358 MILLION - Moomoo
ADICET Bio, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Adicet Bio (NASDAQ:ACET) Posts Earnings Results, Misses Estimates By $0.30 EPS - MarketBeat
Adicet Bio Q2 net loss narrows - TradingView
Adicet Bio reports Q2 2026 net loss $21.4M; cash runway into H2 2027, clinical updates planned - TradingView
Adicet Bio, Inc. 2Q 2026: Revenue $0 Net loss $(21.4)M, EPS $(1.99) — 10-Q Summary - TradingView
ACET: Q2 2026 net loss narrowed 32% year-over-year; cash runway extends into H2 2027 - TradingView
BRIEF-Adicet Bio Q2 Basic EPS USD -1.99 - TradingView
ACET Q2'26 Earnings: EPS estimate is (1.69) USD - tradingview.com
Adicet Bio Inc Azioni (ACET) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):